Literature DB >> 8250074

Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis.

W R Freeman1, D N Friedberg, C Berry, J I Quiceno, M Behette, S C Fullerton, D Munguia.   

Abstract

We studied 259 patients to determine the time-dependent risk and risk factors for the development of retinal detachment in patients with cytomegalovirus retinitis. The six-month and one-year retinal detachment rates (by eye) were 11% and 24%, respectively. Increasing retinal surface involvement outside of the posterior pole and the presence of retinitis activity were found to be the two covariates that best predicted retinal detachment. Eyes with peripheral involvement greater than 25% had a fivefold risk for detachment, compared to eyes with 10% involvement. If there was retinitis activity and more than 25% peripheral (external to major vascular arcades) involvement, the risk increased to 24-fold. The presence of a fellow eye with retinal detachment was not an independent risk factor. These observations should help in the design of a prophylactic trial intended to prevent retinal detachment and should also help ophthalmologists counsel patients with cytomegalovirus retinitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250074     DOI: 10.1016/s0002-9394(14)73471-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  11 in total

1.  Cytomegaloviral retinitis-related retinal detachment: outcomes following vitrectomy in the developing world.

Authors:  Sri K Gore; Daniel M Gore; Kreasen Chetty; Linda Visser
Journal:  Int Ophthalmol       Date:  2013-06-21       Impact factor: 2.031

2.  Cytomegalovirus retinitis: are intraocular devices the answer?

Authors:  A Tufail; G N Holland
Journal:  Br J Ophthalmol       Date:  1995-12       Impact factor: 4.638

3.  Ocular manifestations of HIV infection.

Authors:  D A Jabs
Journal:  Trans Am Ophthalmol Soc       Date:  1995

4.  Retinal detachment associated with AIDS-related cytomegalovirus retinitis: risk factors in a resource-limited setting.

Authors:  Michael Yen; Jenny Chen; Somsanguan Ausayakhun; Paradee Kunavisarut; Pornpattana Vichitvejpaisal; Sakarin Ausayakhun; Choeng Jirawison; Jessica Shantha; Gary N Holland; David Heiden; Todd P Margolis; Jeremy D Keenan
Journal:  Am J Ophthalmol       Date:  2014-10-22       Impact factor: 5.258

5.  High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration.

Authors:  N Morlet; S Young; D Naidoo; G Graham; M T Coroneo
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

Review 6.  Comparative tolerability of therapies for cytomegalovirus retinitis.

Authors:  S Walmsley; A Tseng
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

7.  Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy.

Authors:  D E Goldberg; H Wang; S P Azen; W R Freeman
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

8.  Cytomegalovirus retinitis in the post-cART era.

Authors:  Alexander D Port; Rolake O Alabi; Lisa Koenig; Mrinali P Gupta
Journal:  Curr Ophthalmol Rep       Date:  2018-05-02

9.  CMV retinitis in China and SE Asia: the way forward.

Authors:  David Heiden; Peter Saranchuk
Journal:  BMC Infect Dis       Date:  2011-11-24       Impact factor: 3.090

10.  Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic.

Authors:  David Heiden; Nathan Ford; David Wilson; William R Rodriguez; Todd Margolis; Bart Janssens; Martha Bedelu; Nini Tun; Eric Goemaere; Peter Saranchuk; Kalpana Sabapathy; Frank Smithuis; Emmanuel Luyirika; W Lawrence Drew
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.